Navrogen Enters into CRADA with the U.S. National Cancer Institute to Develop Agents to Overcome Tumor-Mediated Immunosuppression
Philadelphia, PA, October 1, 2019 — Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused on advancing antibody-based experimental medicines to targets associated with tumor-mediated immunosuppression. Researchers at the NCI, led by Dr. Ira Pastan, NIH Distinguished Investigator and co-chief of NCI Center for Cancer Research’s Laboratory of Molecular Biology, have developed compounds that can uniquely target molecules on inflammatory cells and unlock their immuno-suppressed state within the tumor microenvironment. Under this CRADA, Navrogen is responsible for validating and advancing the preclinical development of these compounds towards clinical trials.
“We have been fortunate to work with some of the leading researchers focused on immune-mediated anti-cancer therapies” stated Luigi Grasso, Ph.D., Chief Scientific Officer of Navrogen. The agents focused within this program have been previously shown in early clinical studies to unlock the immune response within tumors, and we hope to leverage their use with new approaches in tumors that exhibit immune suppression of this pathway.”
The CRADA program complements Navrogen’s focus on developing novel agents that can overcome humoral immune suppression which is mediated by tumor-produced humoral immuno-oncology (HIO) factors.
NavrogenTM Inc. is a biotechnology company focused on the discovery of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. Our mission is to develop diagnostic assays that can identify patients whose tumors produce HIO-factors to advise physicians on therapeutic options as well as develop first-in-class agents that can overcome the immuno-suppressive effects of a specific HIO-factor.
Investor Inquiries: Nicholas Nicolaides (CEO), firstname.lastname@example.org +1 (610)-399-2717
Media Inquiries: Steve Kyriakos (VP of Finance & Operations), email@example.com +1 (610)-399-2717